ArticleCerebellum (London, England)2026
Relapsing Seronegative Immune-Mediated Cerebellar Ataxia with Evolving Intrathecal Immune Activation and Rituximab Consolidation in a Toddler: A Case Report.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seronegative immune-mediated cerebellar ataxia in young children is poorly defined and may be mistaken for self-limited post-infectious ataxia when magnetic resonance imaging and antibody panels are negative. A previously healthy 2-year-old girl developed acute cerebellar ataxia with gait instability, frequent falls, limb tremor, and choking while drinking. Brain/cerebellar magnetic resonance imaging was normal. At relapse, an equivocal cervical cord T2 signal was not confirmed on dedicated cervical imaging or accompanied by myelopathic signs. Extensive serum and cerebrospinal fluid antibody testing was negative. Initial cerebrospinal fluid showed mild pleocytosis; oligoclonal bands were reported as negative, although a single cerebrospinal fluid band was noted. She improved after intravenous immunoglobulin and high-dose corticosteroids but relapsed after early steroid discontinuation. At relapse, cerebrospinal fluid pleocytosis increased to 251 × 10⁶/L, with type 2 cerebrospinal fluid-restricted oligoclonal bands and intrathecal immunoglobulin M synthesis. Epstein-Barr virus serology suggested recent infection, but blood and cerebrospinal fluid Epstein-Barr virus DNA were negative. Genetic and metabolic testing was unrevealing. Rituximab was introduced as consolidation therapy after repeat first-line immunotherapy, while oral prednisone was tapered from 1 mg/kg/day to discontinuation in January 2026. Four weekly infusions depleted peripheral B cells, and a fifth infusion was given after B-cell reconstitution. No infusion reactions or infectious complications occurred. The retrospectively estimated Scale for the Assessment and Rating of Ataxia gait/posture subscore improved from 12/18 at relapse to 0/18 during follow-up. This case highlights serial evolution of intrathecal immune activation in relapsing seronegative pediatric cerebellar ataxia and adds pharmacodynamic and clinical follow-up support for the feasibility of B-cell-monitoring-guided rituximab consolidation in selected relapsing cases. Causal efficacy cannot be inferred from a single case treated with intravenous immunoglobulin, corticosteroids, and a subsequent prednisone taper.
Indexed as
Identifiers
42360526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.